Profile data is unavailable for this security.
About the company
Chosa Oncology AB, formerly RhoVac AB, is a Sweden-based biotechnology company. The Company specializes on research and development of immunotherapeutic drugs. The Company's business focus is found in the development of vaccines for the treatment of metastatic cancer. Immunotherapy treatment is an important part of the operation where the body's own immune system is used to fight and eliminate cancer cells. The Company's drug candidate is used in combination with surgery or radiotherapy. Its products are iCIP, which is combines the identification of patients that will benefit from cisplatin treatment with the ability to treat them with higher efficacy and less toxicity; LiPlaCis is a liposomal formulation of cisplatin enabling direct delivery of this known agent to tumor sites; and DRP is a multigene mRNA-based Drug-specific Response Predictor built upon a deep systems biology analysis of all transcriptional (RNA) changes in tumor cells in response to a broad range of drug types.
- Revenue in SEK (TTM)717.00k
- Net income in SEK-6.01m
- Incorporated2015
- Employees--
- LocationChosa Oncology ABMedicon Village, Scheeletorget 1LUND 223 81SwedenSWE
- Phone+46 40832365
- Websitehttps://www.chosaoncology.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Strategic Partners A/S | 0.00 | -4.72m | 33.23m | 1.00 | -- | 1.30 | -- | -- | -83.43 | -83.43 | 0.00 | 433.01 | 0.00 | -- | -- | 0.00 | -18.16 | -66.13 | -19.52 | -94.41 | -- | -- | -- | -- | -- | -69.91 | 0.00 | -- | -- | -- | 98.86 | -- | -- | -- |
| Peptonic Medical AB | 15.69m | -48.98m | 33.61m | 3.00 | -- | 0.481 | -- | 2.14 | -0.0068 | -0.0068 | 0.002 | 0.0037 | 0.1994 | 0.6491 | 3.47 | 2,242,000.00 | -62.23 | -52.80 | -86.90 | -72.84 | 67.85 | 54.48 | -312.10 | -141.78 | 0.2747 | -26.44 | 0.2863 | -- | -27.55 | 43.57 | -40.95 | -- | 11.04 | -- |
| Modus Therapeutics Holding AB | 0.00 | -17.94m | 37.95m | 2.00 | -- | 2.61 | -- | -- | -0.1796 | -0.1796 | 0.00 | 0.1196 | 0.00 | -- | -- | 0.00 | -137.62 | -123.65 | -167.64 | -208.97 | -- | -- | -- | -- | -- | -63.99 | 0.00 | -- | -- | -- | 13.14 | -- | -- | -- |
| 2cureX AB | 25.00k | 3.06m | 44.68m | 0.00 | 8.61 | 71.38 | -- | 1,787.33 | 0.2068 | 0.2068 | 0.0012 | 0.0249 | 0.0041 | -- | 0.0148 | -- | 50.01 | -45.04 | 179.24 | -49.69 | -12,972.00 | -44,478.89 | 12,228.00 | -109,947.80 | -- | -- | 0.00 | -- | -- | -- | 88.14 | -- | -- | -- |
| Larkberget AB | 252.00k | -35.46m | 44.75m | 1.00 | -- | 0.8095 | -- | 177.58 | -1.79 | -1.79 | 0.0127 | 2.79 | 0.0031 | -- | 0.2702 | 25,200.00 | -43.82 | -16.31 | -47.28 | -17.54 | -- | -- | -14,069.77 | -81.71 | -- | -- | 0.00 | -- | -94.13 | -- | -25.83 | -- | -- | -- |
| Acousort AB | 5.62m | -12.36m | 55.45m | 16.00 | -- | 2.97 | -- | 9.88 | -0.7188 | -0.7188 | 0.3101 | 0.8814 | 0.2799 | -0.0274 | 49.25 | 350,937.50 | -61.61 | -48.79 | -81.29 | -71.44 | 101.21 | 63.17 | -220.12 | -285.72 | 4.51 | -- | 0.00 | -- | -14.40 | 20.61 | 11.77 | -- | -- | -- |
| Chosa Oncology AB | 717.00k | -6.01m | 65.48m | -- | -- | 4.06 | -- | 91.33 | -0.0766 | -0.0766 | 0.0096 | 0.2044 | 0.0382 | -- | 0.8639 | -- | -32.00 | -55.65 | -35.30 | -67.69 | 643.24 | -- | -837.66 | -792.50 | -- | -49.05 | 0.00 | -- | -39.73 | -62.56 | 59.93 | -- | -- | -- |
| Lifecare ASA | 1.71m | -116.19m | 72.15m | 28.00 | -- | -- | -- | 42.11 | -2.48 | -2.48 | 0.0379 | -0.11 | 0.0168 | -- | 0.1582 | 55,272.73 | -115.30 | -52.64 | -194.19 | -61.98 | -- | -- | -6,864.75 | -277.39 | -- | -- | 1.17 | -- | -26.10 | 36.13 | -103.52 | -- | -- | -- |
| Opsy Holding AB | 4.13m | -18.69m | 76.18m | 7.00 | -- | 49.33 | -- | 18.45 | -20.83 | -20.83 | 0.6321 | 0.1216 | 0.294 | -- | 7.63 | 2,064,500.00 | -133.11 | -117.68 | -201.35 | -142.11 | 154.30 | -- | -452.72 | -- | -- | -216.84 | 0.463 | -- | -- | -- | -43.22 | -- | -- | -- |
| Spago Nanomedical AB (publ) | 437.00k | -26.55m | 79.39m | 7.00 | -- | 2.58 | -- | 181.67 | -0.0513 | -0.0513 | 0.0008 | 0.0465 | 0.0115 | -- | 4.39 | 62,428.57 | -69.64 | -30.44 | -81.41 | -32.48 | -- | -- | -6,076.43 | -3,410.33 | -- | -- | -- | -- | -77.13 | 5.02 | 18.32 | -- | -- | -- |
| IDL Diagnostics AB (publ) | 52.19m | -39.31m | 85.00m | 22.00 | -- | 0.5681 | -- | 1.63 | -0.1706 | -0.1706 | 0.2266 | 0.6495 | 0.3263 | 6.59 | 5.26 | 2,372,364.00 | -24.58 | -29.04 | -26.98 | -31.14 | 21.53 | 1.70 | -75.32 | -157.60 | 3.29 | -- | 0.0843 | -- | 33.45 | 164.62 | 28.41 | -- | 18.85 | -- |
| Alligator Bioscience AB | 42.25m | -77.72m | 95.14m | 13.00 | -- | -- | -- | 2.25 | -2.16 | -2.16 | 0.6369 | -0.0592 | 0.5013 | -- | 9.35 | 938,822.30 | -92.22 | -97.96 | -- | -155.50 | -- | -- | -183.96 | -569.04 | -- | -- | 1.33 | -- | -0.5851 | 67.68 | 5.91 | -- | -- | -- |
